Canada: Proposed Changes To Canadian Regulation Affecting Generic Drug Submissions And Data Protection

Last Updated: April 26 2019
Article by Eileen McMahon, Teresa A. Reguly and Michele Clarizio

The Canadian government has published proposed amendments to the Food and Drug Regulations (Regulations) that will make it easier for a generic drug manufacturer to bring a chemical variant of an existing innovator drug to market.

What you need to know

  • The proposed Regulations are not law. Stakeholders may provide comments to Health Canada on the proposed Regulations until June 8.
  • Drug manufacturers will be able to submit an Abbreviated New Drug Submission (ANDS) to Health Canada for generic drug products that are a salt, hydrate or solvate of a Canadian reference product (CRP).
  • The proposed Regulations are forward looking: they will only apply to drugs where the regulatory submission for the generic drug product has a filing date after the date the regulations come into force.
  • In connection with this update, the definition of “innovative drug” in Canada’s data protection regulations will be modified. This proposed change is forward looking and would apply to drug submissions filed after the coming into force date.

Notable changes

Increasing the use of the ANDS pathway

In Canada, a drug manufacturer may receive a Notice of Compliance (NOC) to market a generic version of a drug product previously authorized by Health Canada (i.e., an innovator drug). To obtain regulatory approval, a drug manufacturer must file an ANDS with information demonstrating the generic drug product is the “pharmaceutical equivalent” of the CRP (i.e., the previously approved innovator drug). Under section C.08.001.1 of the current Regulations, a generic drug product is considered to be the pharmaceutical equivalent of a CRP if it contains “identical amounts of identical medicinal ingredients.”

In 2003, Health Canada’s official position was that the medicinal ingredient found in the dosage form of the generic drug product had to be chemically identical, but not necessarily physically identical, to that of the CRP to be considered a “pharmaceutical equivalent.” Generic drug manufacturers criticized this interpretation, as it did not account for changes to the form of the active pharmaceutical ingredient that can occur during the manufacturing process of the dosage form. Apotex challenged Health Canada’s position in a proceeding before the Federal Court, and in 2013, the court held that pharmaceutical equivalence could be assessed by comparing the starting ingredients used in manufacturing the dosage form. 1

In response to the Federal Court decision, Health Canada altered its position, and stated that comparing input medicinal ingredients would be acceptable for determining pharmaceutical equivalence for an ANDS. However, if the medicinal ingredient in the generic drug product diverged into a different form than the CRP in the dosage form, Health Canada could request additional safety, effectiveness and quality data. In a 2017 interim policy, Health Canada also expanded the types of drug products that would be eligible for regulatory approval through the ANDS pathway. Specifically, Health Canada stated that different salt forms of a CRP could be eligible for an ANDS.

The proposed Regulations codify Health Canada’s current position with respect to ANDS eligibility. Under the proposed Regulations, ANDS eligibility will no longer be determined by assessing whether the generic drug product contains an “identical medicinal ingredient.” Instead, ANDS eligibility would be determined by assessing whether there is an “identical therapeutically active component.” A “therapeutically active component” will be defined as “a medicinal ingredient, excluding those appended portions, if any, that cause the medicinal ingredient to be a salt, hydrate or solvate.” In other words, generic drug products that are a salt, hydrate or solvate of a CRP will be eligible to be approved through the ANDS pathway.

These amendments will only apply to chemical (small molecule) drugs, and not to radiopharmaceutical drugs or biologics. Health Canada has indicated that the proposed Regulations are aimed at improving access to generic medicines in Canada.

Limitations on data protection

Drug products that fall within the definition of “innovative drug” are entitled to an eight-year term of data protection, which can be extended for an additional six months for pediatric population submissions. The proposed Regulations would update the definition of “innovative drug” in section C.08.004.1 of the Regulations to make it consistent with the other proposed amendments. The following table compares the current definition of “innovative drug” to the definition in the proposed Regulations:

Current Regulations Proposed Regulations
Innovative drug means a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph. Innovative drug means a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient. Variation includes, for the purposes of the definition innovative drug,
  1. an enantiomer or a mixture of enantiomers;
  2. a polymorph;
  3. a medicinal ingredient that, when compared to a previously approved medicinal ingredient, is identical, excluding those appended portions, if any, that cause either medicinal ingredient to be a salt, ester, hydrate, or solvate; or
  4. any combination of the variations found in paragraphs (a) to (c).

What’s next

The proposed Regulations are not law. Stakeholders may provide comments to Health Canada on the proposed Regulations until June 8. Health Canada has also opened public consultations on two draft guidance documents relating to the proposed regulatory changes. Stakeholders may provide comments on the draft guidance documents until June 17.


1 Apotex Inc. v. Canada (Health), 2013 FC 1217.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions